

[Levofloxacin](#)

Essential medicine status

Section:

[6. Anti-infective medicines 6.2. Antibacterials 6.2.5. Antituberculosis medicines](#)

ATC codes: [J01MA12](#)

EMLc

Indication

Multi-drug resistant Mycobacterium tuberculosis ICD11 code: [ML32.00](#)

INN

Levofloxacin

Medicine type

Chemical agent

Antibiotic groups

[WATCH](#)

List type

Core

Additional notes

Medicines for the treatment of multidrug-resistant tuberculosis (MDR-TB) should be used in specialized centres adhering to WHO standards for TB control.

Formulations

Oral > Solid > dispersible tablet: 100 mg (EMLc)

Oral > Solid > tablet: 250 mg ; 500 mg ; 750 mg (EML)

EML status history

First added in 1999 ([TRS 895](#))

Changed in 2003 ([TRS 920](#))

Changed in 2011 ([TRS 965](#))

Changed in 2013 ([TRS 985](#))

Changed in 2017 ([TRS 1006](#))

Changed in 2019 ([TRS 1021](#))

Changed in 2025 ([TRS 1064](#))

Sex

All

Age

Also recommended for children

Therapeutic alternatives

The recommendation is for this specific medicine

Patent information

Patents have expired in most jurisdictions

Read more [about patents](#).

Wikipedia

[Levofloxacin](#)

DrugBank

[Levofloxacin](#)

Summary of evidence and Expert Committee recommendations

The Expert Committee recommended the transfer of listings for medicines for multi-drug resistant tuberculosis from the complementary to the core list of the EML and EMLc.